A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)
Status:
Recruiting
Trial end date:
2025-04-15
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3885125 after
administration of single ascending doses in participants with dyslipidemia (part A) and
multiple doses in participants with non-alcoholic fatty liver disease (part B). Blood tests
will be performed to check how much LY3885125 gets into the bloodstream and how long it takes
the body to eliminate it.
The study will last up to approximately 49 weeks for part A and 62 weeks for part B, for a
total of approximately 111 weeks.